RT Journal Article
SR Electronic
T1 Exploring stroke survivors’ and physiotherapists’ perspectives of the potential for markerless motion capture technology in community rehabilitation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.18.22272596
DO 10.1101/2022.03.18.22272596
A1 Faux-Nightingale, Alice
A1 Philp, Fraser
A1 Leone, Enza
A1 Helliwell, Brinton Boreman
A1 Pandyan, Anand
YR 2024
UL http://medrxiv.org/content/early/2024/03/18/2022.03.18.22272596.abstract
AB INTRODUCTION Many stroke survivors do not receive optimal levels of personalised therapy to support their recovery. Use of technology stroke rehabilitation has increased in recent years to help minimise gaps in service provision. Markerless motion capture technology is currently being used for musculoskeletal and occupational health screening and could offer a means to provide personalised guidance to stroke survivors struggling to access rehabilitation.AIMS This study considered context, stakeholders, and key uncertainties surrounding the use of markerless motion capture technology in community stroke rehabilitation from the perspectives of stroke survivors and physiotherapists with a view to adapting an existing intervention in a new context.METHODS Three focus groups were conducted with eight stroke survivors and five therapists. Data were analysed using reflexive thematic analysis.RESULTS Five themes were identified: limited access to community care; personal motivation; pandemic changed rehabilitation practice; perceptions of technology; and role of markerless technology for providing feedback.CONCLUSIONS Participants identified problems associated with the access of community stroke rehabilitation, exacerbated by Covid-19 restrictions. Participants were positive about the potential for the use of markerless motion capture technology as a means to support personalised, effective stroke rehabilitation in the future, providing it is developed to meet stroke survivor specific needs.Competing Interest StatementProfessor Anand Pandyan has received unrestricted educational support from Allergan and Biometrics Ltd., and Honorarium payments from Allergan, Biometrics Ltd., Ipsen, and Merz. These companies are unlikely to be affected by the research reported in this paper. All other authors have no conflict of interest.Funding StatementThis study was funded by the Stroke Association and MedCity.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received a favourable ethical opinion from Keele University Faculty of Medicine and Health Sciences Research Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData in the present study are not available.